Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A composition comprising a polypeptide and a CpG molecule, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG molecule comprises at least one sulfur atom.

2. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.

3. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises no more than 15 amino acid residues.

4-5. (Canceled)

6. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises a B-X, X-B, or B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.

7. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises an B-X-B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.

8. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least two cysteine residues.

9. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least 4 positively charged amino acid residues.

10. (Original) The composition of claim 1, wherein at least one of said at least one cysteine residue of said CpG-interacting amino acid sequence is adjacent to a positively charged amino acid residue.

11. (Original) The composition of claim 10, wherein said CpG-interacting amino acid sequence comprises the sequence set forth in SEQ ID NO:1 (KCSRNR).

12. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:1 (KCSRNR).

13. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:2 (ACSANA).

14. (Original) The composition of claim 13, wherein said at least one positively charged amino acid residue is an arginine.

15. (Original) The composition of claim 13, wherein said at least one positively charged amino acid residue is a lysine.

16. (Original) The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 50 amino acid residues.

17-19. (Canceled)

20. (Original) The composition of claim 1, wherein said polypeptide is less than 50 amino acid residues in length.

21-23. (Canceled)

24. (Original) The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate linkage.

25. (Canceled)

26. (Original) A method for producing a composition having enhanced immunogenicity, said method comprising:

(a) obtaining a polypeptide having a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, and wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue; and

(b) contacting said polypeptide to a CpG molecule comprising a sulfur atom to form said composition.

27. (Original) The method of claim 26, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.

28-30. (Canceled)

31. (Original) A method for activating a cytotoxic T lymphocyte within a mammal, said method comprising administering a composition comprising a polypeptide and a CpG molecule to said mammal, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG molecule comprises a sulfur atom.

32. (Original) The method of claim 31, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.

33-37. (Canceled)